CereScan Corp. expands its intellectual property with the issuance of a new patent-Neuroimaging Database Systems and Methods

Littleton, CO December 11th, 2014

CereScan Corp. (www.cerescan.com), a state of the art brain imaging and analytics company, is transforming the modern understanding of brain science and neurodiagnostics by developing the country’s largest and most comprehensive data warehouse for analyzing functional brain images and patient clinical information. The United States Patent and Trademark Office recently issued a patent to CereScan for its techniques in analyzing brain conditions. The CereMetrix™ Brain Diagnostic System (BDS) is a brain imaging and diagnostic reference tool that changes the way medical professionals, research institutions, medical device manufacturers and pharmaceutical companies understand brain diagnostics and treatment worldwide. The CereMetrix™ BDS is a robust medical library which includes standard patient health records, coupled with radiological, neurological and psychological diagnoses. Currently, CereMetrix™ includes comprehensive data on thousands of patients with chronic neurological and complex neuropsychiatric conditions.

Each CereScan patient has a unique medical history and neurological makeup. After undergoing neuropsychological assessments and two separate functional brain scans providing quantitative data, the information is then processed and cataloged within the CereMetrix™ BDS along with the patient’s full medical history, clinical symptomology, and demographic information. By aggregating and integrating this valuable clinical information, the CereMetrix™ system can effectively identify combinations of clinical characteristics and perfusion (blood flow) patterns associated with specific chronic brain disorders.

The CereMetrix™ BDS includes hundreds of searchable data elements including each patient’s clinical history, family history, immunizations, presenting symptoms, prior diagnoses, medications and previous treatments, along with a library of high-definition, statistically mapped functional brain images analyzing up to 120 regions of the brain. Our patient records represent a broad spectrum of conditions such as traumatic brain injury (TBI), toxic brain injury, Alzheimer’s Disease and other dementias, bipolar disorder, attention deficit hyperactivity disorder (ADHD), anxiety, autism, depression and other brain disorders. As it continues to grow, the system will become an integrated database with increasingly precise data, and will provide a set of protocols designed to support research and diagnostic applications for patients suffering from chronic brain disorders.

The functional imaging patterns detected by the CereMetrix™ BDS, in conjunction with the aforementioned clinical information, allows doctors to more quickly and accurately diagnose chronic brain conditions, which will spark the development of new and innovative research opportunities, more effective treatment paths, and possible cures for debilitating neurological and neuropsychiatric conditions.

“The application of big data in a medical setting will enhance CereScan’s position as the industry leader in brain health and care,” stated John Kelley, Chief Executive Officer and Chairman of CereScan. “The medical community will be able to evaluate brain based disorders through cutting edge machine learning technology allowing for improved patient diagnosis and treatment.”

With each new patient, the CereMetrix™ BDS will ”learn” more and will further its position as the leading diagnostic tool in identifying and treating brain disorders. CereScan’s diagnostic system is continually being refined and enhanced to include sophisticated searching and reporting functionality that will eventually become the industry standard in effectively diagnosing brain related illnesses, becoming one of the most desired diagnostic tools utilized across the medical industry.

About CereScan:

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technology with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. For clinical patients, CereScan helps them and their physicians better understand the biological basis of their conditions. For forensic cases, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit www.CereScan.com.

CereScan Corp. Selected to Join Cavendish Global and Present at Health Impact Forums

Littleton, CO November 25, 2014

CereScan, a national leader in functional brain diagnostics and molecular imaging, was selected as an Innovation Partner and invited to present at the Cavendish Global Health Impact Forums that took place November 10-13th at Oxford University in the UK and will take place April 27-30, 2015 in San Diego. The Health Impact Forums help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within the health and life sciences. To accomplish this mission, the Forums showcase presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Michael Moffat, Cavendish co-founder and President explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. CereScan’s advanced technologies and pioneering research clearly qualified them as an Innovation Partner and we are delighted that they have joined the Cavendish family.”

“We are honored to be selected as an Innovation Partner and to present our leading-edge research at these unique events. It is further recognition of our innovative approaches in the brain health arena,” said Dr. Richard Fort, CereScan President & COO. “We welcome the opportunity to interact with many of the world’s leading scientific minds, thought-leaders and philanthropic families who are dedicated to the common cause of improving the health and lives of people around the world.”

At the November Health Impact Forum, CereScan presented preliminary results of a research program, the Invisible Brain Injury Project, aimed at assessing a novel treatment for traumatic brain injuries (TBIs). This research program, funded by the Tug McGraw Foundation, recruited veterans who served in the Middle East conflicts and suffered TBIs. The aim of this project is to identify effective treatments of TBI and accelerate their adoption in brain healthcare. Final results of the IBIP will be presented at the next Cavendish Health Impact Forum in April, 2015 in San Diego.

About CereScan:

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technology with a patient-centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative, functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the biological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For brain therapy researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit www.CereScan.com.

About Cavendish Global:

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forums provide family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. For more information, please visit http://cavendishglobal.com.

CereScan Earns ACR Nuclear Medicine Accreditation

 

November 20, 2014

CereScan has been awarded a three-year term of accreditation in nuclear medicine as the result of a recent review by the American College of Radiology (ACR). Nuclear medicine is a branch of medical imaging that uses safe amounts of radioactive material, to diagnose and treat a variety of diseases, including many types of cancers, heart disease, and certain other abnormalities within the body and brain.

The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities satisfying the ACR Practice Guidelines and Technical Standards after a peer-review evaluation by independent, board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures, and quality assurance programs are all assessed. The findings are reported to the ACR Committee on Accreditation, which subsequently provides the practice with a comprehensive report they can use for continuous practice improvement.

“ACR accreditation confirms the quality and validity of our Nuclear Medicine SPECT imaging procedures and will give our research partners and patients added confidence regarding our evaluations,” said Dr. Richard Fort, President & COO of CereScan.

The ACR is a national professional organization serving more than 36,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Since 2009, patients from all over the country and throughout the world have consulted Denver-based CereScan and its leading physicians concerning chronic neurological and psychiatric issues.

Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:

 

 

About CereScan

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technology with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the biological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.

CereScan Extending Reach with Medical Imaging Center in Louisiana

November 13, 2014, Denver, CO

CereScan Corp. is proud to announce a groundbreaking neuroimaging partnership agreement with Diagnostic Imaging Services (DIS) in Metairie, Louisiana. This collaborative effort will expand CereScan’s sophisticated brain diagnostic products and DIS’s state of the art neuroimaging capabilities to adults and children who are suffering from “invisible brain issues.” This partnership creates a powerful combination of cutting edge technologies focused on identifying specific brain related problems in areas such as traumatic brain injury, Alzheimer’s disease, and attention deficit disorder. The State of Louisiana and the southeast region of the country now have easy access to the capabilities that these two companies can deliver to medical professionals who are focused on finding solutions for patients with chronic brain disorders.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Since 2009, patients from all over the country and throughout the world have consulted Denver-based CereScan and its leading physicians concerning chronic neurological and psychiatric issues. By partnering with DIS and their extensive experience in nuclear imaging, this Metairie-center will now offer unmatched functional brain imaging capabilities in the southeast.

Referring and treating medical experts can now rely on CereScan and DIS to offer differentiated diagnoses on a wide array of brain-based disorders including:

· ADD/ADHD · OCD
· Alzheimer’s Disease · Parkinson’s Disease
· Anxiety Disorder · Traumatic Brain Injury
· Bipolar Disorder · Toxic Brain Injury
· Dementia · Learning Disorders
· Depression

“We are excited about the opportunity to team up with Diagnostic Imaging Services in order to serve patients and medical professionals in Louisiana and other nearby states. This business relationship will enable us to further expand our high-quality diagnostic brain imaging capabilities to those patients who are seeking hope and solutions to their mental health problems.” said John Kelley, CEO, at CereScan.

With experienced, friendly and professional staffs and facilities designed specifically for comfort and care, CereScan and DIS are dedicated to excellence in patient care. This market expansion provides patients from all over the country will new options in accessing diagnostic technologies that were not in existence a few years ago.

“DIS has always strived to be innovative, offering exams that take advantage of advanced diagnostic techniques and technology,” said Michael Holmes, Chief Executive Officer of DIS. “Partnering with CereScan is the type of continuing synergy we look for that best serves the local community and beyond in the area of medical imaging,” he added.

About CereScan

CereScan combines state-of-the-art SPECT and PET brain imaging technology with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. For clinical patients, CereScan helps them and their physicians better understand the biological basis of their conditions. For forensic cases, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit www.CereScan.com.

About Diagnostic Imaging Services

DIS is the largest independently-owned outpatient imaging provider in Louisiana. Since 1973, this New Orleans-area organization has offered screening and diagnostic exams in areas such as mammography, magnetic resonance imaging (MRI), computed tomography (CT), PET/CT and nuclear medicine, with locations in Metairie, New Orleans, Marrero, Covington and Slidell, Louisiana.

CereScan Partners with The Denver Post to Shed Light on Child Trauma and SPECT Brain Imaging

The Denver Post published an article as a part of an 8 part investigative series this weekend about how children who are neglected or abused during adolescence are more likely to have brain and body abnormalities in adulthood. The article explains that “Children who are beaten, starved or abandoned are likely to suffer emotional trauma so severe that it can impair the way their bodies and brains grow up — and, if never addressed, cause lifelong health problems.” The article then goes on to discuss some of the newest research in treating neglected and abused children. Dr. Bruce Perry, a researcher at ChildTrauma Academy in Houston, Texas, explains that many of these children are misdiagnosed with a mental disorder when in reality the problem is a “manifestation of trauma.” With the help of Single-Photon Emission Computed Tomography (SPECT) brain imaging, doctors can determine if these children are suffering from a mental disorder or a brain abnormality due to the trauma sustained. As a result of the scan, doctors were able to put these children on a more precise treatment regimen that had them in care for a shorter amount of time. The article also tells the story of Grant Oakes, a man who became the legal guardian of his grandson after the child’s mother, a drug user, was abused by her partner in front of him. As he reached his teens, “the child began using marijuana, skipping school and eventually threatening suicide.” With the help of SPECT brain imaging at CereScan, Oakes’ grandson was diagnosed with Bipolar Disorder and is now on a mood-stabilizing medication. The family says they have seen improvements in his behavior. SPECT scans can help answer questions that families and caregivers of children who have been abused. While these scans can be pricey, they may ultimately save money, for both caregivers and the government, by diagnosing the problem earlier and avoiding therapy on a trial and error basis. “I love this kid, but we went through hell and back,” Oakes said. “If we would do these scans and get people help much earlier, then there would be so much money saved in the court system and in doctor visits, not to mention avoiding the grief that people go through.” To learn more about CereScan visit our website at www.cerescan.com. The Denver Post article can be found here.

Clarifying an ADHD Diagnosis, One Must be Sure Before Being Medicated

Dr. Sheryl Ziegler of CereScan, response to 10/9/12 New York Times article, “Attention Disorder or Not, Pills to Help in School”

A recent article in the New York Times highlighted and brought to the forefront America’s obsession with a quick fix using overmedication in an irresponsible fashion. This time it centers around children. Low income children who are struggling in school and are therefore being treated by doctors who are willing to prescribe them medication, in many cases without a diagnosis, for the sake of helping young children improve their grades and focus in school.

The article does an adequate job pointing out the obvious and inherent flaws with this type of practice as well as the doctor rationale for such medical treatment approaches.

However, what the article does not discuss is a counterpoint for the doctor’s arguments that ADHD has “completely subjective” diagnostic criteria and that ADHD “isn’t binary – you have it or you don’t.” There are in fact, objective diagnostic neuro-imaging techniques available to accurately assess which areas of the brain may or may not be compromised. No longer does it have to be the guessing game days of making psychiatric diagnoses such as ADHD without substantial, statistically relevant support. Physicians can refer their patients to have their brain scanned and then receive an objective and comprehensive report that can help them formulate the best treatment plan for their patient. These treatment plans could include best decisions regarding medications and otherwise.

The challenge with this is money (most insurance plans do not cover these scans yet) and the doctor’s willingness to learn more about these neuro-imaging techniques. In an age of big pharmaceutical dollars, an abundance of advertisements on television for the next pill that can help with just about anything and a society that wants a quick fix we are seeing practices such as those described in the New York Times. We are seeing children of all ages being prescribed medications irresponsibly because families and school systems cannot afford, do not choose or do not know how to access more accurate diagnostic information.

The brain imaging data, provided by CereScan to parents and schools on many occasions challenges this trend, and they will continue to work to gain a broader acceptance in the medical community. Parents and schools are starting to take notice. John Kelley, CEO of CereScan mentions, “We have had increasing numbers of parents and school systems inquire as to exactly what kind of information we can provide them, and whether it can further clarify the question as to whether certain medications can improve a particular students performance in school.” He continues, “It really comes back to the accuracy of the diagnosis handed down, and many parents are weary of putting their children on mind altering medications before they know for sure. That is where CereScan can help, since we offer a way for them to know for sure.”

For a full text of the New York Times article, please go to: [http://www.nytimes.com/2012/10/09/health/attention-disorder-or-not-children-prescribed-pills-to-help-in-school.html?_r=1&pagewanted=all __title__ Attention Disorder or Not, Pills to Help in School]

-Dr. Sheryl Gonzalez Ziegler

Dr. Ziegler is the founder and managing director of The Child & Family Therapy Center at Lowry. She is a Counseling Psychologist and Licensed Professional Counselor in the state of Colorado. Dr. Ziegler is a member of the Colorado Association for Play Therapy, American Psychological Association and started the Spousal Forum for the Colorado chapter of Entrepreneur Organization (EO). She is also a consultant to CereScan.

CereScan in the News!

KDVR 31 News in Denver recently aired a segment about CereScan and how we are helping brain-injured soldiers returning from combat. Symptoms of Posttraumatic Stress Disorder (PTSD) and mild traumatic brain injury (mTBI) often overlap and may be misdiagnosed. With the help of SPECT brain imaging, doctors can receive a comprehensive evaluation of the brain which provides more accurate diagnostic information and leads to a more precise treatment path for the individual. To see the full story click here To learn more about SPECT imaging and CereScan, visit our website at www.cerescan.com

Follow

Get every new post delivered to your Inbox.

Join 199 other followers